CHELMSFORD, Mass.--(BUSINESS WIRE)--Apr 29, 2013--ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that results from the Prospective Registry and Follow-Up of Patients Using the Wearable Defibrillator (WEARIT-II) will be presented in a Late-Breaking Clinical Trial presentation at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions, Friday, May 10, 1:30-3:00 p.m., Session number SP22.
The 18-month results from WEARIT-II will be presented by Ilan Goldenberg, MD, (Principal Investigator) University of Rochester Medical Center. WEARIT-II is a prospective, observational study designed to evaluate high cardiac risk patients’ clinical information, arrhythmias, and treatment findings during wearable defibrillator use and subsequent one-year clinical course, including survival.
“As an investigator in the original WEARIT/BIROAD clinical trial and the co-principal investigator for the WEARIT-II Registry, it is rewarding to see that these data will be shared as part of the Late-Breaking Clinical Trial presentations at Heart Rhythm. The LifeVest ® plays an important role in the continuum of care for patients at high risk from sudden cardiac arrest,” said Arthur J. Moss, MD, University of Rochester Medical Center. “The LifeVest allows physicians to protect patients during their period of highest risk early after an acute cardiac event such as a myocardial infarction or newly diagnosed nonischemic cardiomyopathy, when other therapies are not appropriate due to the patient’s changing condition and the potential for cardiac recovery.” “WEARIT-II is the first multi-national registry of LifeVest usage and is currently enrolling patients in the U.S., Europe, and Israel. We look forward to this presentation of the 18-month U.S. results,” said Marshal Linder, President of ZOLL LifeVest. “These data will add to our understanding of the real-world treatment approaches and outcomes from physicians’ utilization of wearable defibrillators.” The LifeVest Wearable Defibrillator, along with sudden cardiac arrest (SCA) education and screening tools, will be on display in Booth #539 at Heart Rhythm 2013 May 8-11 at the Colorado Convention Center in Denver.
LifeVest Provides Protection for Patients at Risk of SCA The LifeVest Wearable Defibrillator protects patients at risk for sudden cardiac arrest. It is used to protect a wide range of patients, including patients with newly diagnosed heart failure, following recent myocardial infarction, or following coronary revascularization. The LifeVest provides protection during this period of high risk, gives physicians time to optimize medical therapy, and helps ensure patients are not lost to follow up.
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.
About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.